Partner with us icon Partner with Us
Corporate Actions
Zydus Life spurts as board to mull share buyback; arm signs deal to acquire Assertio

14-May-26   16:15 Hrs IST
As of 31 March 2026, the promoter and promoter group owned a 75% shareholding in the company.

Meanwhile, the company's subsidiary, Zydus Worldwide DMCC (Zydus Worldwide) through its wholly owned acquisition subsidiary Zara Merger Sub Inc., has signed a definitive agreement with Assertio Holdings, to acquire all outstanding shares of Assertio for $ 23.50 per share in cash. The deal represents total consideration of approximately $166.4 million on a fully-diluted basis, calculated using the treasury stock method.

Assertio is a U.S. based pharmaceutical company focused on specialty and oncology supportive-care therapies with its novel product ROLVEDON (eflapegrastim xnst), approved by USFDA for long-acting G CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. Its turnover was $ 68.23 million in current year 2025.

This transaction will help Zydus to secure an immediate U.S. specialty oncology commercial footprint in the U.S and serves as a platform to expand its oncology specialty portfolio. Assertio's over 170 community oncology accounts and buy-and-bill infrastructure are expected to strengthen Zydus' oncology platform.

Under the terms of the merger agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock. The transaction will be followed by a merger, subject to customary closing conditions, including the tender of a majority of Assertio's outstanding shares. Subsequently, Zydus will acquire the untendered shares through a second-step merger at the same offer price.

The tender offer is expected to commence within five business days following the date of the merger agreement. The transaction is expected to close in the financial year 2026-27, subject to satisfaction of all closing conditions.

Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

On a consolidated basis, Zydus Lifesciences' net profit rose 1.82% to Rs 1042.10 crore while net sales rose 32.34% to Rs 6780.40 crore in Q3 December 2025 over Q3 December 2024.

Powered by Capital Market - Live News

Attention Investors:
Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. || KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. || No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.